Apollo Hospitals and Max Healthcare shares rallied after Macquarie upgraded both stocks. Apollo hit a record high of Rs 9,205, while Max jumped 4% to Rs 1,090. Macquarie said, "Newly commissioned facilities utilisation has been strong," which should help growth. The brokerage expects better earnings as valuations have cooled down.

Apollo Hospitals and Max Healthcare rally after Macquarie upgrades both stocks, seeing up to 34% upside.

The Apollo Hospitals share price skyrocketed to a fresh record high of Rs 9,205 apiece, up over 5% from the previous close, while Max Healthcare share price soared over 4% to a three-month high of Rs 1,090 apiece.

Double upgrades for two hospital stocks

Global brokerage Macquarie double upgraded both the stocks to 'Outperform' from 'Underperform' as it believes consensus earnings have bottomed out for the sector and valuations have cooled down.

The brokerage raised its target price on Apollo Hospital to Rs 10,500, implying an upside of around 15% from the current price of Rs 9,168 apiece. It raised the price target on Max to Rs 1,450 apiece, which reflects an upside of 34% from the current price of Rs 1,081.50 apiece.

"We believe consensus earnings revisions largely factor in the near-term drag from new capacities. Newly commissioned facilities utilisation has been strong, which should accelerate ramp-up and limit the duration of margin dilution. Meanwhile, high utilisation at mature hospitals provides scope for payor-mix optimisation and further margin improvement, helping cushion the drag from new capacity," the brokerage said.

Why Macquarie prefers Max Healthcare

Macquarie prefers Max Healthcare as it offers a better risk-reward. The company's focused capital allocation, modestly better earnings before interest, tax, depreciation, and amortisation (EBITDA) growth, and a more favourable capacity ramp up, makes it the preferred bet.

The brokerage expects Max's revenue to grow at a compounded annual growth rate (CAGR) of 20% over FY26 to FY29. It forecast the company's EBITDA to grow at 22% CAGR over the same period.

Macquarie has raised Max's FY27 consolidated earnings expectation by 2%, while maintaining the FY28 forecast. It also raised the company's FY29 estimated pro-forma EV/EBITDA multiple to 30 times from 22 times. The stock currently trades at 29 times one-year forward EV/EBITDA, compared to its five-year average of 31 times.

Max Healthcare's consensus FY28 and FY29 EBITDA estimates have declined 12% and 11%, respectively, over the past 12 months. Expectations for EBITDA per operating bed on a CAGR basis over FY25 to FY28 have also moderated to 5% from 10%. This reset leaves the FY28 and FY29 consensus expectations at more realistic levels, the brokerage said.

Apollo Hospitals and Max Healthcare: What lies ahead?

Both the companies are set to benefit in the coming quarters as new capacity ramp ups are at a healthy pace. The consensus earnings for the sector have bottomed out and valuations have cooled down, reflecting further growth potential.